#Ireland #Dublin #SHL Medical #Ensera #Argonaut Manufacturing

Ensera Launches Alliance Network for Injectable Solutions

In a significant move to revolutionize the commercialization of injectable drug programs, Ensera has introduced the Ensera Alliance Network. This network connects industry leaders specializing in device platforms and fill-finish services, including SHL Medical, Stevanato Group, Ypsomed, Argonaut Manufacturing Services, and American Injectables. As the landscape of drug-device combination products becomes increasingly complex, Ensera's network is designed to streamline processes and forge stronger connections across the supply chain.

Bringing a drug-device combination product to market often involves multiple specialized suppliers. Pharmaceutical companies typically coordinate among various stakeholders for the device platforms, fill-finish services, final assembly, and packaging. Each point of handover in this chain can introduce complications, potentially delaying progress when responsibilities, timelines, and processes are not aligned. "Too many combination product programs are slowed by disconnected suppliers and difficult handovers," stated Bobby O'Connor, the Chief Commercial Officer at Ensera.

The Ensera Alliance Network aims to address these issues by providing pharmaceutical companies with a more cohesive and responsive model. It seeks to simplify the commercialization process by improving the coordination of critical stages like device platform selection, fill-finish, assembly, and packaging. O'Connor emphasizes that this new alliance helps customers reduce risks and expedite their path to market launch.

Darren Hieber, Ensera's VP of Alliance Partnerships, notes that the foundation of this network relies on established relationships and shared experiences among participating organizations. By leveraging these connections, the network fosters collaboration tailored to the specific needs of individual programs, enabling earlier identification of challenges. This proactive approach helps clients navigate the complexities associated with transitioning to commercial supply effectively.

As part of Ensera's vision for the future, the company plans to expand its alliance network. The aim is to integrate more organizations that enhance the capabilities and goals of existing partners, thus adapting to the evolving demands of customers. Importantly, participation in the Ensera Alliance Network is non-exclusive, maintaining the independence of participant companies. This structure allows clients the flexibility to engage individual firms directly, depending on their specific requirements.

About Ensera

Ensera is a global Contract Development and Manufacturing Organization (CDMO) that specializes in supporting pharmaceutical and medical device companies. Their services encompass device design, manufacturing, final assembly, labeling, and secondary packaging, particularly for injectable formats such as auto-injectors and prefilled syringes. With flexible GMP-compliant cleanroom operations based across Europe, the United States, and Asia, Ensera is well-equipped to handle low-to-medium batch volumes, backed by robust quality assurance systems and cold chain infrastructure. The company's expertise in both pharmaceutical and device sectors enables it to respond effectively to the complexities involved in delivering combination products to the market efficiently.

For more detailed information on Ensera's innovative Alliance Network and its members, please visit www.ensera.com/ensera-alliance-network.